Clinical trial
LITT and Pembrolizumab in Recurrent Brain Metastasis
NCT04187872
Study timeline
Study start (actual)2020-01-10Date precision: day
Registry last updated2023-12-27
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Melanomaunresolved
Non-small Cell Lung Carcinoma (NSCLC)unresolved
Renal Cell Carcinoma (RCC)unresolved
Small-cell Lung Cancerunresolved
Head and Neck Squamous Cell Cancerunresolved
Classical Hodgkin Lymphomaunresolved
Urothelial Carcinomaunresolved
Microsatellite Instability-High Cancerunresolved
Gastric Cancerunresolved
Esophageal Cancerunresolved
Cervical Cancerunresolved
Hepatocellular Carcinomaunresolved
Merkel Cell Carcinomaunresolved
Brain Metastases, Adultunresolved
Interventions
LITT + PembrolizumabCOMBINATION_PRODUCT
Sponsors & collaborators
University of Floridalead sponsor
Monteris Medicalcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04187872 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.